Development of the carbocyclic nucleoside MDL 201449A: A tumor necrosis factor-α inhibitor

Organic Process Research and Development

Volumn 2, Issue 6, 1998, Pages 357-365

  Watson, Timothy J N ^a   Curran, Timothy T ^a,b   Hay, David A ^a,c   Shah, Ramnik S ^a   Wenstrup, David L ^a   Webster, Mark E ^a  

^a SANOFI   (France)

^b PFIZER INC   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343962846     PISSN: 10836160     EISSN: None     Source Type: Journal    
DOI: 10.1021/op9701245     Document Type: Article

References (6)

1. (a) Edwards, C. K., III; Borcherding, S. M.; Zhang, J.; Borcherding, D. B. The Role of Tumor Nercosis Factor-α in Acute and Chronic Inflammatory Responses: Novel Therapeutic Approaches. In Xenobiotics and Inflammation; Schook, L. B., Laskin, D. L., Eds.; Acedemic Press: New York, 1994; pp 97-136.
2. (b) Borcherding, D. R.; Peet, N. P.; Munson, R.; Zhang, H.; Hoffman, P. F.; Bowlin, T. L.; Edwards, C. K., III. J. Med. Chem. 1996, 39, 2615-2620.
3. (a) Curran, T. T.; Hay, D. A.; Koegel C. P.; Evans, J. C. Tetrahedron 1997, 53, 1983.
4. (b) For a complete list of cis-2-cyclopentene-1,4-diol derivatives, see ref 1 of ref 2a.
5. (c) Watson, T. J. N. Chemical Development of MDL 201449A. Presentation at the Midwest Pharmaceutical Process Chemistry Consortium, Cincinnati, OH, October 10, 1997. A copy of slides can be obtained from Tim Watson: Hoechst Marion Roussel Research Institute, 2110 E. Galbraith Rd., Cincinnati, OH 45215-6300.
6. Owen, L. N.; Smith, P. N. Alicyclic Glycols 1952, 4035-4047.